Related Experiment Video

Updated: Apr 26, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Glutathion-S-Transferase P1 polymorphisms association with broncopulmonary dysplasia in preterm infants

P Karagianni1, D Rallis1, L Fidani2

  • 12nd NICU and Neonatology Department, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Greece.

Hippokratia
|July 18, 2014
PubMed

Insights

This study investigated glutathione-S-transferase P1 (GSTP1) gene polymorphisms in relation to bronchopulmonary dysplasia (BPD) in preterm infants. Results indicate no significant association between GSTP1 polymorphisms and BPD development or severity.

Area of Science:

  • Neonatal Medicine
  • Genetics
  • Respiratory Medicine

Background:

  • Oxidative stress is implicated in bronchopulmonary dysplasia (BPD) pathogenesis.
  • Glutathione-S-transferase P1 (GSTP1) is a key antioxidant enzyme with identified polymorphisms.
  • Understanding genetic predispositions like GSTP1 polymorphisms is crucial for BPD research.

Purpose of the Study:

  • To investigate the potential association between GSTP1 gene polymorphisms and the risk of developing BPD.
  • To determine if GSTP1 polymorphisms correlate with the severity of BPD in preterm infants.

Main Methods:

  • A prospective case-control study was conducted.
  • GSTP1 genetic polymorphisms were analyzed in 28 preterm infants with BPD and 74 controls (preterm infants without BPD and healthy term infants).

Main Results:

  • The homozygous ile isomorph of GSTP1 was predominant across all groups.
  • No significant differences in GSTP1 genetic distribution were observed between BPD cases and controls.
  • GSTP1 polymorphisms were not found to be associated with the development or severity of BPD.

Conclusions:

  • This study did not find evidence supporting an association between GSTP1 polymorphisms and BPD.
  • Further research may be needed to explore other genetic factors in BPD pathogenesis.
Abstract

Keywords:
Bronchopulmonary dysplasiagenetic predispositionglutathione-S-transferase polymorphismprematurity

More Related Videos

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

14.4K
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

864

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
1.3K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.2K